# A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

> **NCT00106847** · PHASE3 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 683 (actual)

## Conditions studied

- Psoriasis
- Parapsoriasis

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT00106847
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 683 (ACTUAL)
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106847, "A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00106847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*